Media stories about Galapagos (NASDAQ:GLPG) have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Galapagos earned a news impact score of 0.24 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.4400236436901 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- ETFs with exposure to Galapagos NV : December 7, 2017 (finance.yahoo.com)
- Technical Views: Tracking the Numbers on Shares of Galapagos Nv (GLPG) – Lockport Press (lockportpress.com)
- Galapagos (GLPG) Downgraded to Sell at ValuEngine (americanbankingnews.com)
- Galapagos (GLPG) Downgraded by BidaskClub to “Strong Sell” (americanbankingnews.com)
A number of equities research analysts have issued reports on the stock. Stifel Nicolaus raised shares of Galapagos from a “hold” rating to a “buy” rating and raised their price target for the stock from $83.00 to $101.00 in a report on Friday, August 11th. Zacks Investment Research raised shares of Galapagos from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. BidaskClub lowered shares of Galapagos from a “sell” rating to a “strong sell” rating in a report on Saturday, December 2nd. Nomura raised their price target on shares of Galapagos from $108.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, August 11th. Finally, BTIG Research reissued a “buy” rating and issued a $118.00 price target on shares of Galapagos in a report on Monday, November 20th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. Galapagos currently has an average rating of “Hold” and a consensus price target of $111.00.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.